To correlate 3 T Magnetic Resonance Spectroscopic Imaging (MRSI) with prostate specific antigen (PSA) in patients with prostate cancer (PC) treated with external beam radiation therapy to assess potential advantages of MRSI. 50 patients (age range 65-83 years) underwent PSA and MRSI surveillance before and 3,6,12,18 and 24 months after radiotherapy. Of the 50 patients examined, 13 patients completely responded to therapy showing metabolic atrophy (MA), defined as a choline-plus-creatine-to-citrate ratio (CC/C) < 0.2, at 3 months; in this group none had biochemical relapse (BR) (PSA nadir + 2 ng/mL) by the end of the follow-up. 35 patients out of 50 showed partial response to therapy (0.2 < CC/C < 0.8) at 3 and 6 months. 30 out of these 35 patients reached MA at 12 month, while 5 developed a recurrence (CC/C > 0.8). 3 of those with recurrence had a BR at 18 months and the other 2 at 24 months. 2 out of the 50 patients did not respond to the treatment showing persistent disease from the 3rd month (CC/C > 0.8); one patient showed BR at 6 and the other at 12 months. MRSI shows a greater potential than PSA in monitoring patients after radiotherapy, because it anticipates PSA nadir and especially BR. This article is protected by copyright. All rights reserved.

Metabolic Atrophy and 3T 1H - MR Spectroscopy Correlation After Radiation Therapy for Prostate Cancer / Panebianco, Valeria; Barchetti, Flavio; Daniela, Musio; Forte, Valerio; Alberto, Pace; DE FELICE, Francesca; Barchetti, Giovanni; Tombolini, Vincenzo; Catalano, Carlo. - In: BJU INTERNATIONAL. - ISSN 1464-410X. - ELETTRONICO. - (2014), pp. n/a-n/a. [10.1111/bju.12553]

Metabolic Atrophy and 3T 1H - MR Spectroscopy Correlation After Radiation Therapy for Prostate Cancer.

PANEBIANCO, VALERIA;BARCHETTI, FLAVIO;FORTE, VALERIO;DE FELICE, FRANCESCA;Barchetti, Giovanni;TOMBOLINI, Vincenzo;CATALANO, Carlo
2014

Abstract

To correlate 3 T Magnetic Resonance Spectroscopic Imaging (MRSI) with prostate specific antigen (PSA) in patients with prostate cancer (PC) treated with external beam radiation therapy to assess potential advantages of MRSI. 50 patients (age range 65-83 years) underwent PSA and MRSI surveillance before and 3,6,12,18 and 24 months after radiotherapy. Of the 50 patients examined, 13 patients completely responded to therapy showing metabolic atrophy (MA), defined as a choline-plus-creatine-to-citrate ratio (CC/C) < 0.2, at 3 months; in this group none had biochemical relapse (BR) (PSA nadir + 2 ng/mL) by the end of the follow-up. 35 patients out of 50 showed partial response to therapy (0.2 < CC/C < 0.8) at 3 and 6 months. 30 out of these 35 patients reached MA at 12 month, while 5 developed a recurrence (CC/C > 0.8). 3 of those with recurrence had a BR at 18 months and the other 2 at 24 months. 2 out of the 50 patients did not respond to the treatment showing persistent disease from the 3rd month (CC/C > 0.8); one patient showed BR at 6 and the other at 12 months. MRSI shows a greater potential than PSA in monitoring patients after radiotherapy, because it anticipates PSA nadir and especially BR. This article is protected by copyright. All rights reserved.
2014
radiation therapy; prostate cancer; spectroscopy
01 Pubblicazione su rivista::01a Articolo in rivista
Metabolic Atrophy and 3T 1H - MR Spectroscopy Correlation After Radiation Therapy for Prostate Cancer / Panebianco, Valeria; Barchetti, Flavio; Daniela, Musio; Forte, Valerio; Alberto, Pace; DE FELICE, Francesca; Barchetti, Giovanni; Tombolini, Vincenzo; Catalano, Carlo. - In: BJU INTERNATIONAL. - ISSN 1464-410X. - ELETTRONICO. - (2014), pp. n/a-n/a. [10.1111/bju.12553]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/531180
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 12
social impact